No recent company-specific news was identified. Recent news items relate to other companies and market conditions.

• The company has not reported any revenue since the second quarter of 2022 and has not purchased inventory since that time, indicating a pause in operations [S1].
• The sole part-time CEO resigned in August 2025, and the company currently has no full-time employees [S1].
• Financial statements as of June 30, 2026, show a net loss of $21,356 for the six months ended June 30, 2026, and a current ratio of 0.01, reflecting liquidity challenges [S2].

The company’s focus on cordyceps, a traditional medicinal product with established demand in Asia, provides a niche market opportunity. If the company can secure funding and successfully implement its business plan, it may develop complementary products and expand its customer base. The potential to market products in the US and other western markets exists, subject to regulatory compliance and operational execution.

The company has not generated revenue since mid-2022 and has minimal cash and current assets relative to liabilities, indicating financial distress. The resignation of its sole part-time CEO and lack of employees raise concerns about operational continuity. The company faces significant risks including inability to raise funds, regulatory compliance challenges, intense competition, and uncertain market acceptance of its products. These factors may impair its ability to continue as a going concern.

The company lacks significant competitive advantages such as proprietary technology, patents, or strong brand recognition. Its reliance on third-party suppliers and distributors, combined with minimal operational scale and funding constraints, limits its ability to establish a durable moat. The cordyceps market is competitive with several better-capitalized and better-known players, which further challenges the company's market position.

• Funding Risk: The company relies on funding from a minority stockholder and the CEO with no assurance of continued support, which may impair its ability to implement its business plan.
• Operational Risk: Minimal staffing and the resignation of the sole part-time CEO create risks for business continuity and execution of operations.
• Regulatory Risk: Compliance with dietary supplement regulations in the US and other countries requires significant resources; failure to comply may result in penalties or inability to market products.
• Market and Competition Risk: The company competes with better-known and better-capitalized firms in the cordyceps market, limiting its ability to gain market share.
• Financial Risk: The company has a current ratio of 0.01 and a cash ratio of 0.48 as of June 30, 2026, indicating liquidity constraints and a stockholders' deficit.

• ACRO BIOMEDICAL CO., LTD. is a Nevada corporation incorporated on September 24, 2014, with a name change on January 30, 2017 following a change of control.
• Since 2017, the company has focused on developing and marketing nutritional products promoting wellness and a healthy lifestyle, primarily cordyceps-related products.
• Cordyceps is a fungus used in traditional Chinese medicine, sourced from suppliers in Taiwan; the company has purchased from three suppliers, with one accounting for all purchases in 2022.
• The company has not generated revenue since the second quarter of 2022 and has not purchased inventory since that time.
• All sales to date have been sales of cordyceps-related products except for a one-time sale of metallothionein MT-3 elizer in 2018, which is no longer sold.
• The company’s business plan is in preliminary stages and requires significant funding to implement, with no assurance of success.
• The sole employee was the CEO who worked part-time and resigned in August 2025; all sales were conducted by him.
• At December 31, 2025, the company had nominal cash, no accounts receivable, and no inventory.
• The company’s financing since January 1, 2021 has primarily come from a minority stockholder and the CEO, with no assurance of continued funding.
• The company’s products are sold to distributors who may use them as ingredients; the company does not manufacture products itself.
• The company faces regulatory requirements in the US and other countries for dietary supplements, including FDA regulations and labeling requirements.
• The company has no patents or intellectual property rights related to its products.
• Competition includes several better-known and better-capitalized companies marketing cordyceps products in the US and Asia.
• The company had total current assets of $3,648 and current liabilities of $448,437 as of June 30, 2026, resulting in a current ratio of 0.01 and a cash ratio of 0.48.
• The company reported zero revenue and a net loss of $21,356 for the six months ended June 30, 2026.
• The company had 60,042,000 shares of common stock issued and outstanding as of August 5, 2026.
• The company’s accumulated deficit was $32,824,071 and stockholders’ deficit was $444,789 as of June 30, 2026.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.